The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In some embodiments, the AS are provides in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomem of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma. In some embodiments, the method are provided to predict the effectiveness of antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R) in a subject.

The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications.

Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.

The present disclosure provides compositions and methods for the treatment of subjects having a risk of invasive breast cancer. In some embodiments, these aspects allow for the pairing of the proper treatment option for the particular subject. In some embodiments, this allows for identifying subjects who, while at risk for invasive breast cancer, will not normally respond to radiation therapy, and can instead receive an alternative therapy, such as a HER2 antibody.

Provided are methods for treatment of cancer. Also provided are methods for treating a patient susceptible or suspected of being susceptible with anti-CD47 therapies.

The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anticancer treatment in a sample of a subject by detecting oncogenic and cancer related proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer.

The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.

A method of diagnosing, staging or monitoring cancer, the method comprising the steps of: (a) providing a sensor array comprising at least two sensors, wherein each sensor comprises a protein barrel that comprises five or more alpha helices arranged as an alpha-helical barrel, and a reporter dye, wherein the protein barrel defines a lumen, the reporter dye is bound to the lumen reversibly; and wherein the protein barrel is different in structure in the at least two sensors; (b) contacting the sensor array with a sample obtained from a patient; and then (c) comparing the sensor array to a predetermined standard.

Disclosed herein are biomarkers and methods of using the same for determining the risk of recurrence of cancer in a subject. The methods may include determining the level of expression of at least one MHCII gene, determining the level of expression of at least one TIL gene, and determining an Immune Activation Score for the subject. Further provided are methods of diagnosing a subject with triple-negative breast cancer (TNBC) as having TNBC Basal-like subtype, and methods of treating cancer in a subject.

Disclosed herein are methods for identifying one or more diseased cells in a subject. Some embodiments include providing a biological sample derived from a subject, analyzing the biological sample by mass spectrometry, and determining the abundance of one or more lipids in the biological sample, wherein an altered abundance of the one or more lipids in the biological sample, as compared to a reference level, indicates a presence of one or more diseased cells in the subject from which the biological sample is derived.